Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Resistance-Based Multicomponent Training Plus Nutrition Supplementation for Intrinsic Capacity and Disability Risk in Chinese Rural Older Adults

16 giugno 2026 aggiornato da: Yongzhao Fan, Capital University of Physical Education and Sports, China

Effect of Resistance-Led Multicomponent Training Combined With Nutritional Supplementation on Intrinsic Capacity and Disability Risk in Chinese Rural Older Adults

This study is a five-arm, parallel-group, assessor-blinded randomized controlled trial designed to evaluate the effects of resistance-dominant multicomponent training combined with nutritional supplementation on intrinsic capacity and disability risk among rural Chinese older adults. A total of 220 participants aged 60 years or older with mobility decline, nutritional risk, sarcopenia risk, or pre-frailty/frailty will be randomly assigned to one of five groups: control, nutrition supplementation alone, resistance training alone, resistance training plus nutrition supplementation, or resistance-dominant multicomponent training plus nutrition supplementation. The intervention will last 12 weeks. Exercise interventions will be conducted three times per week, and nutritional supplementation will include leucine-enriched whey protein and vitamin D. The primary outcomes are the Short Physical Performance Battery score, FRAIL score, and activities of daily living/instrumental activities of daily living scores. Secondary outcomes include gait speed, Timed Up and Go test, sit-to-stand performance, handgrip strength, nutritional status, protein intake, serum 25-hydroxyvitamin D, calf circumference, and appendicular skeletal muscle mass index.

Panoramica dello studio

Descrizione dettagliata

This study aims to determine whether resistance-dominant multicomponent training combined with leucine-enriched whey protein and vitamin D supplementation can improve intrinsic capacity and reduce disability risk in rural Chinese older adults. The study focuses on the locomotion and vitality domains of intrinsic capacity, which are closely related to mobility function, nutritional status, muscle reserves, and the ability to maintain independent daily living.

Eligible participants will be rural community-dwelling adults aged 60 years or older who present at least one of the following risk characteristics: reduced physical performance, low gait speed, nutritional risk, sarcopenia risk, or pre-frailty/frailty. After baseline assessment, participants will be randomly allocated in a 1:1:1:1:1 ratio to one of five study groups: control group, nutrition supplementation group, resistance training group, resistance training plus nutrition supplementation group, and resistance-dominant multicomponent training plus nutrition supplementation group.

The traditional resistance training program will include progressive functional resistance exercises such as chair sit-to-stand, chair-assisted squat, calf raise, elastic-band knee extension, elastic-band hip abduction, elastic-band rowing, wall push-up, and shoulder press. The resistance-dominant multicomponent training program will use resistance training as the core component and will additionally include balance, gait, aerobic, flexibility, and breathing relaxation exercises. Exercise sessions will be conducted three times per week for 12 weeks.

The nutritional supplementation will consist of approximately 20 g/day whey protein, 2.5-3.0 g/day total leucine, and 800-1000 IU/day vitamin D3. The supplement will be administered twice daily. On training days, one dose will be taken within 30 minutes to 2 hours after exercise, and another dose after breakfast. On non-training days, the supplement will be taken after breakfast and dinner.

Outcome assessments will be performed at baseline and at week 12. The primary outcomes are the Short Physical Performance Battery score, FRAIL score, and activities of daily living/instrumental activities of daily living scores. Secondary outcomes include 4-meter gait speed, Timed Up and Go test, five-times sit-to-stand test, 30-second chair stand test, handgrip strength, Mini Nutritional Assessment Short Form score, daily protein intake, serum 25-hydroxyvitamin D, body mass index, calf circumference, appendicular skeletal muscle mass index, and quality of life. Safety outcomes include renal function, blood calcium, falls, musculoskeletal injury, gastrointestinal symptoms, and other adverse events.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

220

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Henan
      • Jiaozuo, Henan, Cina, 454000
        • Rural Community Sites in Jiaozuo, Henan

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  1. Aged 60 years or older.
  2. Rural residents who have lived in the study area for at least 6 months and have no plan for long-term absence during the study period.
  3. Able to walk independently or with a cane for a short distance.
  4. Meeting at least one of the following risk characteristics: Short Physical Performance Battery score of 9 or lower, usual gait speed of 0.8 m/s or lower, Mini Nutritional Assessment Short Form score of 11 or lower, SARC-F score of 4 or higher, possible sarcopenia according to the Asian Working Group for Sarcopenia 2019 criteria, or FRAIL score of 1 to 3.
  5. Able to understand the study requirements and provide written informed consent.

Exclusion Criteria:

  1. Unstable cardiovascular or cerebrovascular events within the past 6 months.
  2. Severe uncontrolled hypertension, defined as resting systolic blood pressure of 180 mmHg or higher or diastolic blood pressure of 110 mmHg or higher.
  3. Severe cognitive impairment that prevents understanding of or cooperation with the study procedures.
  4. Severe osteoarticular disease or neurological disease affecting exercise safety.
  5. Severe renal dysfunction, such as estimated glomerular filtration rate lower than 30 mL/min/1.73 m², or considered unsuitable for protein supplementation by the study physician.
  6. Hypercalcemia, active kidney stones, or contraindications to vitamin D supplementation.
  7. Allergy to whey protein or any component of the nutritional supplement.
  8. Regular use of protein powder, beta-hydroxy-beta-methylbutyrate, creatine, or other nutritional supplements that may affect muscle metabolism within the past 3 months.
  9. Participation in another interventional study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Control Group
Participants in this group will receive routine health education and an isocaloric placebo without structured exercise training for 12 weeks.
Participants will receive routine health education during the 12-week study period. The health education will include general advice on healthy aging, physical activity safety, balanced diet, fall prevention, and chronic disease self-management. Participants will not receive structured exercise training or active nutritional supplementation as part of this intervention.
Participants will receive an isocaloric placebo that is similar to the active nutritional supplement in appearance, taste, packaging, and administration frequency. The placebo will be administered during the 12-week study period.
Sperimentale: Nutrition Supplementation Group
Participants in this group will receive leucine-enriched whey protein and vitamin D supplementation without structured exercise training for 12 weeks.
Participants will receive a nutritional supplement containing approximately 20 g/day whey protein, 2.5 to 3.0 g/day total leucine, and 800 to 1000 IU/day vitamin D3. The supplement will be administered twice daily for 12 weeks. On training days, one dose will be taken within 30 minutes to 2 hours after exercise, and the other dose will be taken after breakfast. On non-training days, the supplement will be taken after breakfast and dinner.
Sperimentale: Resistance Training Group
Participants in this group will receive supervised progressive resistance training three times per week for 12 weeks and an isocaloric placebo.
Participants will receive an isocaloric placebo that is similar to the active nutritional supplement in appearance, taste, packaging, and administration frequency. The placebo will be administered during the 12-week study period.
Participants will complete supervised progressive resistance training three times per week for 12 weeks, with each session lasting 45 to 60 minutes. Exercises will include chair sit-to-stand, chair-assisted squat, calf raise, elastic-band knee extension, elastic-band hip abduction, elastic-band rowing, wall push-up, and shoulder press. Training intensity will progress from RPE 3-4/10 during weeks 1-4, to RPE 5-6/10 during weeks 5-8, and RPE 6-7/10 during weeks 9-12.
Sperimentale: Resistance Training Plus Nutrition Group
Participants in this group will receive supervised progressive resistance training three times per week for 12 weeks combined with leucine-enriched whey protein and vitamin D supplementation.
Participants will receive a nutritional supplement containing approximately 20 g/day whey protein, 2.5 to 3.0 g/day total leucine, and 800 to 1000 IU/day vitamin D3. The supplement will be administered twice daily for 12 weeks. On training days, one dose will be taken within 30 minutes to 2 hours after exercise, and the other dose will be taken after breakfast. On non-training days, the supplement will be taken after breakfast and dinner.
Participants will complete supervised progressive resistance training three times per week for 12 weeks, with each session lasting 45 to 60 minutes. Exercises will include chair sit-to-stand, chair-assisted squat, calf raise, elastic-band knee extension, elastic-band hip abduction, elastic-band rowing, wall push-up, and shoulder press. Training intensity will progress from RPE 3-4/10 during weeks 1-4, to RPE 5-6/10 during weeks 5-8, and RPE 6-7/10 during weeks 9-12.
Sperimentale: Resistance-Dominant Multicomponent Training Plus Nutrition Group
Participants in this group will receive supervised resistance-dominant multicomponent training three times per week for 12 weeks combined with leucine-enriched whey protein and vitamin D supplementation.
Participants will receive a nutritional supplement containing approximately 20 g/day whey protein, 2.5 to 3.0 g/day total leucine, and 800 to 1000 IU/day vitamin D3. The supplement will be administered twice daily for 12 weeks. On training days, one dose will be taken within 30 minutes to 2 hours after exercise, and the other dose will be taken after breakfast. On non-training days, the supplement will be taken after breakfast and dinner.
Participants will complete supervised resistance-dominant multicomponent training three times per week for 12 weeks, with each session lasting 50 to 65 minutes. The program will use resistance training as the core component and will also include balance, gait, aerobic, flexibility, and breathing relaxation exercises. Each session will include approximately 25 to 30 minutes of resistance training, 8 to 10 minutes of balance and gait training, 8 to 10 minutes of aerobic exercise, and 5 minutes of stretching and relaxation.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in Short Physical Performance Battery Score at Week 12
Lasso di tempo: Baseline and Week 12
The Short Physical Performance Battery will be used to assess lower-extremity physical performance, including standing balance, 4-meter gait speed, and five-times sit-to-stand performance. Total scores range from 0 to 12, with higher scores indicating better physical performance.
Baseline and Week 12
Change From Baseline in FRAIL Score at Week 12
Lasso di tempo: Baseline and Week 12
The FRAIL scale will be used to assess frailty status. The scale includes fatigue, resistance, ambulation, illness, and loss of weight. Scores range from 0 to 5, with higher scores indicating greater frailty risk.
Baseline and Week 12
Change From Baseline in Activities of Daily Living Score at Week 12
Lasso di tempo: Baseline and Week 12
Activities of daily living will be assessed to evaluate basic self-care ability in daily life. Higher scores indicate better basic daily living function.
Baseline and Week 12
Change From Baseline in Instrumental Activities of Daily Living Score at Week 12
Lasso di tempo: Baseline and Week 12
Instrumental activities of daily living will be assessed to evaluate more complex daily living abilities. Higher scores indicate better instrumental daily living function.
Baseline and Week 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: yongzhao f, PhD, Henan Normal University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

18 giugno 2025

Completamento primario (Effettivo)

15 gennaio 2026

Completamento dello studio (Effettivo)

31 gennaio 2026

Date di iscrizione allo studio

Primo inviato

16 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 giugno 2026

Primo Inserito (Effettivo)

22 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared because the study involves personal health information from rural older adults, and no formal data-sharing plan or participant consent for public data sharing has been established.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Routine Health Education

3
Sottoscrivi